Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 23, Issue 4, Pages 271-282
Publisher
Informa UK Limited
Online
2018-11-14
DOI
10.1080/14728214.2018.1547707
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy
- (2018) Christopher C. Mills et al. CANCER RESEARCH
- Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo
- (2018) Carmela Ciccarelli et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure
- (2018) Susan Slovin et al. JAMA Oncology
- Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
- (2017) Justin Guinney et al. LANCET ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- The expression of AURKA is androgen regulated in castration-resistant prostate cancer
- (2017) Kati Kivinummi et al. Scientific Reports
- Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling
- (2017) Styliani Karanika et al. Cell Reports
- Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
- (2017) Semini Sumanasuriya et al. Cold Spring Harbor Perspectives in Medicine
- Therapeutic Approaches Targeting MYC-Driven Prostate Cancer
- (2017) Richard Rebello et al. Genes
- Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
- (2017) Mirjana Efremova et al. Frontiers in Immunology
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
- (2016) H. Beltran et al. ANNALS OF ONCOLOGY
- A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
- (2016) Jianqing Lin et al. ONCOLOGIST
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
- (2015) Gerald S. Falchook et al. Drugs in research & development
- Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
- (2015) Juan Miguel Mosquera et al. NEOPLASIA
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells
- (2014) Liangliang Liu et al. PLoS One
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Dual inhibition of autophagy and the AKT pathway in prostate cancer
- (2013) Francois Lamoureux et al. Autophagy
- Castration-resistant prostate cancer: Adaptive responses in the androgen axis
- (2013) Alison Egan et al. CANCER TREATMENT REVIEWS
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
- (2013) Rhonda L Bitting et al. ENDOCRINE-RELATED CANCER
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Therapy: Targeting Cell Cycle Regulators
- (2012) Martin Johansson et al. Anti-Cancer Agents in Medicinal Chemistry
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Point Mutations in the Human Androgen Receptor: Classification of Mutations on the Basis of Transcriptional Activity
- (2012) Colin W. Hay et al. PLoS One
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes
- (2011) J. L. Wright et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2011) Ming Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- The AR dependent cell cycle: Mechanisms and cancer relevance
- (2011) Matthew J. Schiewer et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2
- (2011) Rodrigo Dienstmann et al. Recent Patents on Anti-Cancer Drug Discovery
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
- (2010) A H M Reid et al. BRITISH JOURNAL OF CANCER
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Whether to target single or multiple CDKs for therapy? That is the question
- (2010) Józefa Węsierska-Gądek et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin-dependent kinase inhibitors as potential targeted anticancer agents
- (2009) Ivan Diaz-Padilla et al. INVESTIGATIONAL NEW DRUGS
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
- (2008) Robert W. Ross et al. CANCER
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now